Navigation Links
DiaCarta Inc. Receives CE Mark for QuantiVirus® HPV E6/E7 mRNA Assay

Hayward, CA (PRWEB) March 15, 2013

DiaCarta Inc., an in vitro diagnostic company for infectious diseases, cancer and other indications, today announced it has received CE Mark approval for its QuantiVirus® HPV E6/E7 bDNA test, a highly sensitive and specific test for the detection of 14 high-risk types of the human papilloma virus (HPV) for cervical and head and neck cancer screening.

The QuantiVirus® HPV E6/E7 bDNA test assays the mRNA expression of the viral E6 and E7 oncogenes providing a more accurate correlation of HPV infection and the potential development of cancer.

“We are very encouraged with our sales launch in China of the QuantiVirus® HPV E6/E7 test for cervical cancer screening through our China affiliate, Kodia Biotechnology Inc. and look forward to providing the QuantiVirus® HPV test in other territories as well as expanding its clinical application for head and neck cancer screening” said Dr. Aiguo Zhang, founder and CEO of DiaCarta. “Our bDNA based E6/E7 mRNA test is the most reliable tool to detect high risk HPVs directly from Pap smear for women cervical cancer screening or directly from saliva for head and neck cancer test without RNA purification and RT-PCR.”

About Human Papillomavirus (HPV)
Genital human papillomavirus (also called HPV) is the most common sexually transmitted infection (STI). There are more than 40 HPV types that can infect the genital areas of males and females of which 14 types are most commonly associated with cervical cancer. These HPV types can also infect the mouth and throat where HPV plays a direct role in head and neck cancer. Most people who become infected with HPV do not know they have it so it is recommended that woman between ages 21 and 65 have regular Pap smears, which examines cervical cells for the presence of irregular and potentially pre-malignant or malignant cells, as well as testing directly for the presence of HPV. With regular Pap and HPV screening and follow-up, cervical cancer is one of the most preventable female cancers.

About DiaCarta Inc.
DiaCarta, based in Hayward, Calif., is developing and commercializing in vitro diagnostics for a wide range of diseases based on branched DNA (bDNA) Signal Amplification technology (Siemens, Germany) and CytoPlexTM, a proprietary multiplex technology platform. This combination of detection technology provides DiaCarta with broad capabilities to detect nucleic acid (DNA, mRNA, miRNA) and proteins for diagnostic applications. In addition, DiaCarta offers a suit of biomarker validation and companion diagnostic development services including a cytokine panel for drug-induced cytotoxicity screening, gene expression measurement services based on bDNA and companion diagnostic development based on our bDNA and multiplexing technology platforms.

About Kodia Biotechnology Inc.
Kodia Biotechnology Inc. was formed in 2009, which is an affiliate of DiaCarta in China. Kodia is focusing on sFDA application process and commercialization of DiaCarta’s products in the region. Kodia was awarded with innovative high technology company from local government and has built 1200 square feet of GMP facility for molecular Diagnostic products. The facility has been ISO13485 certified.

For more information, please contact:
James Erickson
Chief Operating Officer

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Lyncean Technologies, Inc. receives $1.1M grant from DOE to develop the Compact Light Source
3. Boulder Canyon Natural Foods Receives Non-GMO Project Verified Seal For Its Kettle-Cooked Chips
4. Bentley Receives $1.3M to Advance the Integration of Science and Business
5. iBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards
6. Zyomyx, Inc. Receives ISO 13485: 2003 Certification
7. New Science Fiction Novel Paints Terrifying Picture of Dystopian Future: Young Author Receives Glowing Reviews
8. Rosemary Gladstar Receives First-Annual ABC Mark Blumenthal Herbal Community Builder Award
9. Next Breath Receives ISO/IEC 17025:2005 Accreditation from the American Association for Laboratory Accreditation
10. OsteoFab™ Patient Specific Cranial Device Receives 510(k) Approval
11. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
Post Your Comments:
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):